請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54582
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭瑞祥 | |
dc.contributor.author | Kuo-Chih Tseng | en |
dc.contributor.author | 曾國枝 | zh_TW |
dc.date.accessioned | 2021-06-16T03:05:48Z | - |
dc.date.available | 2020-07-20 | |
dc.date.copyright | 2015-07-20 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-06-26 | |
dc.identifier.citation | 一、 中文參考資料
1. 朱道凱譯,1999,平衡計分卡—資訊時代的策略管理工具,臉譜文化出版。 Kaplan, R.S. and Norton, D.P 1996.The balanced scorecard: Translating Strategy into Action。 2. 吳安妮,2002,淺談平衡計分卡成功實施之精髓概念,會計研究月刋,198期,第26-32頁。 3. 吳安妮,2007,平衡計分卡整合性管理制度,經理人月刊,30期,第156-165頁。 4. 吳安妮,2008,平衡計分卡之發展歷程及其角色,平衡計分卡:化策略為行動的績效管理工具,新版專文導讀,臉譜出版。 5. 林子瑜、程馨與陳寬政,2013,台灣癌症盛行率與死亡率的替換關係1996-2006,健康與社會 1:125-143。 6. 林毅志,2012,地區醫院應用平衡計分卡導入心導管中心的模式探討,國立臺灣大學管理學院碩士在職專班會計與管理決策組碩士論文。 7. 許祐寧,2006,醫療機構導入平衡計分卡過程之研究-以某公立醫院為例,長庚大學醫務管理研究所碩士論文。 8. 陳正平等譯,2004,策略地圖-串聯組織策略從形成到徹底實施的動態管理工具,臉譜出版。Kaplan, R.S. and Norton, D.P.Converting intangible assets into tangible outcomes。 9. 陳自諒,2012,平衡計分卡於醫療實務之應用-以私立醫學中心大腸直腸外科為例,國立交通大學 高階主管管理學程碩士班 碩士論文。 10. 陳欣怡, 2007,建構醫院之策略地圖與平衡計分卡-以某區域教學醫院為例,國立成功大學會計學系研究所碩士論文。 11. 陳建仁,2006,台灣十大死因的三十年變遷,健康世界,241: 6-13。 12. 黃世傑,2006,組織轉型與策略核心組織之建構:台大醫院雲林分院個案研究,國立臺灣大學管理學院高階公共管理組碩士論文。 13. 楊銘欽、董鈺琪、陳進堂、黃莉蓉與顏志展,2009,醫療健康產業平衡計分卡理論與實務一書,台北,華杏。 14. 蔡玉娟,2007,公立教學醫院科部平衡計分卡之設計-以麻醉部為例,成功大學高階管理碩士在職專班碩士論文。 15. 劉鐘軒、蔡正中與陳海雄,2013,肝癌的診斷及治療最新發展 內科學誌24:85-94。 16. 駱文淵,2004,平衡計分卡在會計師業應用之研究─以某中型會計師事務所為例, 國立台灣大學會計學研究所碩士論文。 二、 英文參考資料 1. Beasley RP, Hwang LY, Lin CC, et al. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet, 2(8256): 1129-1133. 2. Bruix J, Sherman M. 2011. American Association for the Study of Liver Diseases Management of Hepatocellular Carcinoma: An Update Hepatology, 53(3): 1020-1022. 3. Chang MH, You SL, Chen CJ, et al. 2009. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst, 101: 1348-1355. 4. Chen CH, Yang PM, Huang GT, et al. 2007. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc, 106(2): 148-155. 5. Chen CJ, Yang HI, Su J, et al. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 295(1): 65-73. 6. Dienstag JL, McHutchison JG. 2006. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology, 130: 231-264; quiz 214-217. 7. Donato F, Tagger A, Gelatti U, et al. 2002.Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol, 155: 323-331. 8. El-Serag HB. 2011. Hepatocellular Carcinoma.N Engl J Med, 365: 1118-1127. 9. El–Serag HB, Hampel H, Javadi F. 2006. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol, 4: 369-380. 10. El-serag HB, Tran T, Everhart JE.2004.Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology, 126: 460-468. 11. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer.2012. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 56:908–943. 12. Fattovich G, Stroffolini T, Zagni I, et al. 2004. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 127: Suppl 1: S35-S50. 13. Forner A, Reig ME, de Lope CR, et al. 2010.Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis, 1: 61-74. 14. Hsu YC, Ho HJ, Wu MS, et al. 2013. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology, 58: 150-157. 15. Iloeje UH, Yang HI, Su J, et al. 2006. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 130(3): 678-686. 16. Kaplan RS, Norton DP. 1992. The balanced scorecard- measures that drive performance. Harvard Business Review, pp.71-79. 17. Kaplan RS, Norton DP. 1993. Putting the balanced scorecard to work. Harvard Business Review, pp.134-147. 18. Kaplan RS, Norton DP. 1996. Using the Balanced Scorecard as a Strategic Management system. Harvard Business Review, pp.75-85. 19. Kaplan RS, Norton DP. 2000. The Strategy-Focused Organization – How Balanced Scorecard Companies Thrive in the New Business Environment, Harvard Business School Press. 20. Kaplan RS, Norton DP. 2001. Transforming the Balanced Scorecard from Performance Measurement to Strategic Management: PartI. Accounting Horizons, 15(1), pp.87-104. 21. Lauer GM, Walker BD. 2001. Hepatitis C virus infection.N Engl J Med, 345: 41-52. 22. Lee MH, Yang HI, Lu SN, et al.2010. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma:long-term predictors from a community-based cohort study. J Clin Oncol, 28: 4587-4593. 23. Liaw YF, Sung JJ, Chow WC, et al. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351: 1521-1531. 24. Liu CJ, Chu YT, Shau WY, et al. 2014. Treatment of patients with dual hepatitis C and B by perinterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.Gut, 63: 506-514. 25. Llovet JM, Ricci S, Mazzaferro V, et al. 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359: 378-390. 26. Neuschwander‐Tetri BA, Caldwell SH. 2003. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.Hepatology, 37: 1202-1219. 27. Niven PR. 2002. Balanced Scorecard Step-by-Step: Maximizing performance and maintaining results. New York: John Wiley & Sones. 28. Omata M, Lesmana LA, Tateishi R, et al. 2010. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int, 4:439–474. 29. Salem R, Lewandowski RJ, Kulik L, et al. 2011. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with HCC. Gastroenterology,140: 497–507. 30. Silva MA, Hegab B, Hyde C, et al. 2008. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut, 57: 1592-1596. 31. Wu CY, Chen YJ, Ho HJ, et al. 2012. Association between nucleoside analogues and risk of hepatitis B virusrelated hepatocellular carcinoma recurrence following liver resection. JAMA, 308: 1906-1914. 32. Wu CY, Lin JT, Ho HJ, et al. 2014. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B- a nationwide cohort study. Gastroenterology, 147: 143-151. 33. Yang HI, Lu SN, Liaw YF, et al. 2002. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 347(3): 168-174. 34. Yu ML, Lin SM, Chuang WL, et al. 2006. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antiviral therapy, 11(8): 985-994. 三、網站資料 1. 內政部統計處-簡易生命表 http://www.moi.gov.tw/stat/life.aspx 2. 國民健康署-癌症登記線上互動查詢系統https://cris.hpa.gov.tw/ 3. 衛生福利部統計處(2014)。死因統計。 http://www.mohw.gov.tw/cht/DOS/。 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54582 | - |
dc.description.abstract | 肝病是國病,肝癌更是十大癌症死因之第二名。以2013年為例,肝和肝內膽管癌死亡人數為肝癌8217人。此外,該年度亦有4843人因慢性肝病死亡。總計台灣一年約有一萬三千人死於肝病。個案醫院所處的雲嘉縣市,屬肝癌高發生率與死亡率地區。在肝病的臨床處理上,除了肝膽科醫師外,亦橫跨了一般外科、影像醫學科、放射腫瘤科、腫瘤科、病理科等,因此跨科別團隊的合作,在肝癌的處理上益形重要。
平衡計分卡是由柯普朗與諾頓所共同發展出來績效衡量系統,不僅強調績效的評估要在財務、顧客、流程、學習與成長四個構面間達到平衡,更進而把它當成策略管理及組織溝通的工具,以達成組織願景;是醫療機構一項很好的管理工具。 個案醫院為區域教學醫院,其經營宗旨為「守護生命,守護健康,守護愛」,也提出其願景為:1.加強資源整合達到永續經營的目的、2.提供全人全程的卓越醫療品質,成為雲嘉最被信賴的醫院、3.樹立人本醫療的典範。為實現醫院的願景,醫院在2013年導入平衡計分卡,並選定肝癌作為肝癌團隊執行的目標之一。團隊在管理專家的協助下,從資料蒐集,文獻探討,肝癌實證醫學的論證,使用SWOT分析團隊所處的位置,進而擬定肝癌策略地圖,計有策略一:建立權威性之醫療、策略二:建立全人全程的人本醫療典範、策略三:建立社區醫療之服務模式、策略四:強化資源與資訊系統整合,以提升營運與成本管理效率;並擬定關鍵衡量指標內容,目標值與行動方案。並適時開始執行。總計在財務構面有2項指標,病人構面有7項指標、流程構面有13 項指標、學習與成長構面有3項指標。經過一年的調整,約有86.4%指標達成或部分達成,但團隊發現有些關鍵衡量指標並不關鍵;有些收集困難,亦無法量化,也將於年度平衡計分卡會議建議修正刪除。 平衡計分卡的成功要素文獻有諸多探討,對肝癌以平衡計分卡在本院實施而言,確實可讓團隊用較寬廣的心來面對與處理跨科醫療或跨醫療與非醫療或跨團隊事務,初不習慣,進而逐漸孰悉;而依作者而言,平衡計分卡欲成功,領導者的親身參與,上下協調人力、設備與資訊的到位,團隊成員共識及現有評估制度的連結是重要的關鍵因素。 | zh_TW |
dc.description.abstract | Liver disease is the “national” disease of Taiwan. Hepatocellular carcinoma ranks second in deaths caused by malignancies in Taiwan. In 2013, for example, there are 8217 deaths due to liver and intrahepatic bile duct cancers. In addition, 4843 people died from chronic liver disease in the same year. A total of about thirteen thousand people die from liver disease per year. The “case” hospital in discussion is located in Yunlin-Chiayi area, where a high incidence and mortality rate of liver cancer had been observed. In the clinical management of liver disease, the physician specialist in hepatobiliary diseases often needs the joint participation of specialists from general surgery, interventional radiology, radiation therapy, oncology, and pathology. Good teamwork across these disciplines is the most important factor in the successful treatment of liver cancer.
Balanced Scorecard, jointly developed by Kaplan & Norton, is a performance measurement system that stresses the balance of assessment among the four perspectives, namely financial, customer, business processes, and learning and growth. In turn it can be used as policy management and organizational communication tools to achieve organizational vision. Thus it is also a very good medical management tool. The “case” hospital is a regional teaching hospital. She strives to be 'the guardian of life, the guardian of health, and the guardian of love'. Her visions are: 1. integration of resources to achieve the objective of sustainable operation; 2. provision of excellent quality of medical care for the whole person, becoming the most trusted hospital in Yunlin and Chiayi counties; 3. becoming the model of humanistic medical care. To achieve these visions, the hospital adopted the Balanced Scorecard in 2013 and selected liver cancer as the leading practice model. A special team was formed, and, with the assistance of management experts, started to collect data, explore the literature, extract evidence-based medicine for liver cancer treatment, and use SWOT analysis to develop liver cancer strategy map. Four strategies were named: I: the establishment of an authoritative medical care system; II: the establishment of a humanistic medical care model; III: the establishment of a community health service model; and IV: strengthening integration of resources and information systems, in order to enhance operational efficiency and cost management. The BSC team then developed key performance indicators, target measures and action plans. The BSC program was timely executed. In summary, there are two indicators in financial perspective, seven indicators in patients’ perspective, thirteen indicators in internal business process perspective, and three indicators in learning and growth perspective. After a year of execution, 86.4 percent of KPI was achieved or partially achieved, but the team found that some KPIs are not critical; some are difficult to collect; some cannot be quantified. These KPIs will be proposed to be deleted in the BSC annual meeting. Factors of success have been discussed in the Balanced Scorecard literature. The implementation of the Balanced Scorecard in liver cancer management in our hospital did broaden the team's views in dealing with affairs among different specialties, and between medical and non-medical caregivers. In the beginning, members of the team were not comfortable with scorecard because of the unfamiliarity, but gradually everyone learned. The author feels that, to be successful in applying Balanced Scorecard to the management of clinical problem, a good leadership, adequate supply of manpower, equipment and information technology, fair team consensus, and seamless connectivity with the existing assessment system are essential. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T03:05:48Z (GMT). No. of bitstreams: 1 ntu-104-P01748003-1.pdf: 4255928 bytes, checksum: fe60d0412f7f09ca7cf01e9db75dd246 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 目錄
誌謝 iii 摘要 iv Abstract vi 目錄 viii 圖目錄 x 表目錄 xii 第一章、緒論 1 第一節、研究背景與動機 1 第二節、研究目的 1 第二章、文獻探討 2 第一節、台灣肝癌現況 2 第二節、肝癌的診斷與治療:強調早期發現早期治療 12 第三節、平衡計分卡與策略地圖的理論與特色 20 第四節、建立平衡計分卡之流程 28 第五節、平衡計分卡與策略地圖在醫療產業運用之實例分析 34 第三章、研究方法及步驟 40 第一節、計畫緣起 40 第二節、研究流程 40 第四章、個案醫院平衡計分卡結果 42 第一節、個案醫院介紹與現況 42 第二節、擬定肝癌的策略地圖 47 第三節、擬定關鍵衡量指標內容、目標值與行動方案 48 第四節、平衡計分卡執行結果 63 第五章、研究建議與限制 76 第一節、平衡計分卡關鍵成功的因素 76 第二節、解讀個案醫院平衡計分卡資料及分析相關原因 78 第三節、研究限制與建議 80 參考文獻 81 附錄 86 圖目錄 圖2-1、2003-2013年全台肝癌標準化死亡率 ……………………………………5 圖2-2、2003-2013年男、女肝癌標準化死亡率……………………………………6 圖2-3、1986-2011年全台肝癌標準化發生率………………………………………7 圖2-4、1986-2011年男、女肝癌標準化發生率……………………………………8 圖2-5、1994-2011年嘉義市肝癌標準化發生率……………………………………9 圖2-6、1994-2011年嘉義縣肝癌標準化發生率…………………………………9 圖2-7、1994-2011年雲林縣肝癌標準化發生率…………………………………9 圖2-8、2013年肝和肝內膽管癌死亡率縣市地圖………………………………10 圖2-9、2003-2013年雲嘉三縣市肝癌標準化死亡率……………………………11 圖2-10、肝癌的診斷標準 ………………………………………………………14 圖2-11、肝癌的BCLC分期………………………………………………………15 圖2-12、肝硬化的Child-Pugh分級………………………………………………16 圖2-13、肝癌的治療原則…………………………………………………………18 圖2-14、平衡計分卡之四個構面架構圖…………………………………………21 圖2-15、平衡計分卡的四大構面:七大要素、四個系統 ………………………24 圖2-16、平衡計分卡四個構面之因果關係………………………………………26 圖2-17、非營利機構的平衡計分卡架構…………………………………………34 圖2-18、成大醫院麻醉科策略地圖………………………………………………37 圖3-1、本院肝癌平衡計分卡導入流程………………………………………… 40 圖4-1、個案醫院的宗旨、願景及目標………………………………………… 43 圖4-2、個案醫院的策略地圖…………………………………………………… 44 圖4-3、個案醫院的肝癌及六大中心支援架構…………………………………46 圖4-4、個案醫院之肝癌策略地圖………………………………………………47 圖4-5、個案醫院肝病中心病患收案架構………………………………………55 圖4-6、個案醫院肝病中心一次性整合收案流程………………………………55 圖4-7、個案醫院肝病中心肝癌個管系統………………………………………56 表目錄 表2-1、1996-2013年台灣國民平均餘命(單位:歲) ………………………………2 表2-2、1996 年與2013年十大死因標準化死亡率(每十萬人口) ………………3 表2-3、1996 年與2013年十大癌症標準化死亡率(每十萬人口) ………………4 表2-4、2003-2013年全台肝癌標準化死亡率……………………………………6 表2-5、1986-2011年全台肝癌標準化發生率………………………………………7 表2-6、1994-2011年嘉義市、嘉義縣及雲林縣肝癌標準化發生率………………10 表2-7、平衡計分卡之發展脈絡…………………………………………………22 表2-8、SWOT 模型………………………………………………………………31 表2-9、某教學醫院之平衡計分卡及策略衡量指標……………………………35 表2-10、四大構面的策略主題、策略目標與指標………………………………38 表2-11、某區域醫院心導管中心之平衡計分卡…………………………………39 表3-1、個案醫院肝癌平衡計分卡團隊運作大事纪……………………………41 表4-1、個案醫院核可及現行各類床別數表……………………………………42 表4-2、個案醫院平衡計分卡之衡量指標內容、目標值與行動方案……………57 | |
dc.language.iso | zh-TW | |
dc.title | 平衡計分卡在肝癌的應用:
以南部一區域教學醫院為例 | zh_TW |
dc.title | Applications of Balanced Scorecard in Hepatocellular Carcinoma:A Case study of a Regional Teaching Hospital in Southern Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳俊忠,余峻瑜 | |
dc.subject.keyword | 平衡計分卡,肝癌,策略地圖, | zh_TW |
dc.subject.keyword | Balanced scorecard,Hepatocellular carcinoma,Liver cancer,Strategy map, | en |
dc.relation.page | 94 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-06-27 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 商學組 | zh_TW |
顯示於系所單位: | 商學組 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 4.16 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。